Dr. David Rubinsztein to present at the 6th Aging Research for Drug Discovery Forum in Basel
Credit: Insilico Medicine
Thursday, March 14, 2019 – Today Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, and the Scheibye-Knudsen Lab, University of Copenhagen, announce the presentation of David C Rubinsztein, Ph.D., Professor of Molecular Neurogenetics, Deputy Director, Cambridge Institute for Medical Research, at the 6th Aging Research, Drug Discovery, and AI Forum during the Basel Life Congress, September 10-12, 2019, Basel, Switzerland.
Dr. David Rubinsztein will give a talk titled “Leucine signals to mTORC1 via its metabolite acetyl-coenzyme A” covering the mechanism for mTORC1 regulation by Leucine metabolism at the 6th Aging Research, Drug Discovery, and AI Forum.
“The mechanistic target of rapamycin – mTOR complex 1 is a master regulator of cell growth and metabolism. Leucine activates mTORC1 and many have tried to identify the mechanisms whereby cells sense Leucine in this context. I will describe how the Leu metabolite acetyl-coenzyme A (AcCoA) positively regulates mTORC1 activity by EP300-mediated acetylation of the mTORC1 regulator, Raptor, at K1097. Leucine metabolism and consequent mTORC1 activity are regulated by intermediary enzymes. As AcCoA is a Leucine metabolite, this process directly correlates with Leucine abundance and does not require Leucine sensing via intermediary proteins, as has been described previously. Importantly, we describe that this pathway regulates mTORC1 in a cell-type specific manner. Finally, we observed decreased acetylated Raptor, inhibited mTORC1 and EP300 activity in fasted mice tissues. These results provide a direct mechanism for mTORC1 regulation by Leucine metabolism,” said David C Rubinsztein, Ph.D., Professor of Molecular Neurogenetics, Deputy Director, Cambridge Institute for Medical Research, Professor, UK Dementia Research Institute.
“Over the last 5 years, the “Aging & Drug Discovery” and “AI for Healthcare” forums have been leading events at BaselLife, attracting hundreds of delegates from over 50 countries. This year, we are combining the 2 platforms into a 3 day-event titled “the 6th Aging, AI and Drug Discovery Forum” to explore the convergence of these 2 cutting edge disciplines. Under the program leadership of Professor Morten Scheibye-Knudsen and Dr. Alex Zhavoronkov, with distinguished scientists and industry experts in the field, we look forward to exploring breakthroughs for this great healthcare need for the planet,” said Dr. Bhupinder Bhullar, Chair, Innovation Forum program committee, Basel Life 2019.
“The 6th annual Aging Research, Drug Discovery, and AI Forum at Basel Life will have a fresh program featuring some of the most prominent scientists and industry players in aging and longevity research covering the theory, applications and convergence of these three exciting areas,” said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
“Today we are very excited about announcing the talk from Professor David Rubinsztein, Cambridge University. Professor Rubinsztein continues to pioneer the field of autophagy and neurodegeneration, an area that is under tremendous growth. We are therefore very happy that he is able to add to our exciting program in Basel,” said Morten Scheibye-Knudsen, MD, PhD University of Copenhagen.
The 6th Aging Research for Drug Discovery Forum Basel will bring together leaders in the aging, longevity, and drug discovery field, to describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity’s most challenging problems: aging. The Forum will be held in Basel, Switzerland, September 10-12, 2019.
Contact: Ola Popova
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s Disease, Alzheimer’s Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/
About Basel Life 2019
In this symposium, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity’s most challenging problems: aging. A panel of thought-leaders will give us their cutting edge reports on the latest progress in our quest to extend the healthy lifespan of everyone on the planet.
Conference Official Website: https:/
About Cambridge Institute of Medical Research (CIMR)
CIMR is a unique partnership between basic and clinical research, aiming to understand the cellular basis of disease. Our goal is to create an inspiring environment in which outstanding scientists can excel. By providing state-of-the-art core facilities and support for our researchers, we foster new collaborations that spark discoveries about fundamental cellular processes and their relevance in disease.
The research vision of the CIMR is centred on our strengths in fundamental cell biological processes, with particular emphasis on membrane trafficking, organelle function, protein homeostasis and folding, the cytoskeleton and autophagy. Interactions between researchers are strengthened by common interests in particular disease areas in which we have established expertise: neurodegenerative disease; haematological disorders; immunological and infectious diseases, and cancer.
Institute Website: https:/
About the Scheibye-Knudsen Laboratory
The growing proportion of the elderly population represents an increasing socioeconomic challenge, not least because of age-associated diseases. It is therefore increasingly pertinent to find interventions for age-associated diseases such as Alzheimer’s, Parkinson’s and cardiovascular diseases. Although the cause of aging is currently unknown accumulation of damage to our genome, the DNA, may be a contributing factor.
In the Scheibye-Knudsen lab we try to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of aging in model organisms. These findings suggest that normal aging and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.
Laboratory website: http://scheibye-knudsen.
About the University of Copenhagen
With over 40,000 students and more than 9,000 employees, the University of Copenhagen is the largest institution of research and education in Denmark and among the highest ranked universities in Europe. The purpose of the University – to quote the University Statute – is to ‘conduct research and provide further education to the highest academic level’. Approximately one hundred different institutes, departments, laboratories, centres, museums, etc., form the nucleus of the University.
University Website: http://introduction.